La Jolla Pharmaceutical Company
http://lajollapharmaceutical.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From La Jolla Pharmaceutical Company
Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial
An option fee from potential program acquirer TuHura has enabled Kineta to resume enrolling a Phase I/II study of a VISTA-targeted antibody that the company thinks has best-in-class potential.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
Finance Watch: Clouds Still Darken Biopharma Sector Despite Sunny Forecasts
Restructuring Edition: The industry emerged from the J.P. Morgan Healthcare Conference feeling renewed confidence about deal-making and financing, but drug developers continue to run short on cash or cut programs and jobs before the money runs out, including Cara, PMV and Ikena.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- La Jolla Pharma, LLC
- Tetraphase Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice